ArticleBioanalysis2025
Simultaneous estimation of donepezil and quercetin using ultra high performance liquid chromatography: pharmaceutical and pharmacokinetic applications in Alzheimer's disease.
Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stem cell and CRISPR/Cas9 gene editing technology in Alzheimer's disease therapy: from basic research to clinical innovation.Frontiers in genome editing · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) affects over 55.2 million individuals globally with current treatment modalities only providing symptomatic relief. This highlights the importance of combination therapies which target multiple pathways simultaneously. Donepezil (DNP), an acetylcholinesterase inhibitor, when combined with Quercetin (QCT), a polyhydroxy flavonoid with neuroprotective properties, might alter progression. However, simultaneous estimation of DNP and QCT for concurrent delivery, calls for robust analytical method that can simultaneously estimate both drugs. RESEARCH DESIGN AND
methodsA simple, robust, and cost-friendly UHPLC method for simultaneous estimation of DNP and QCT was developed. The analytes were resolved on C18 column (Kromasil C18, 4.6 × 250 mm), with acetonitrile and 0.1% diethyl amine buffer, adjusted to pH 3.5 with glacial acetic acid as mobile phase in ratio 50:50 v/v at 0.6 mL/min, at column oven temperature 40°C in total analysis run time of 10 min.
resultsDNP and QCT were quantified by PDA detector at 268 nm and 370 nm, respectively. The developed method was found to be linear, accurate, precise, specific, and robust as per ICH guidelines.
conclusionThe developed and validated method efficiently quantified DNP and QCT co-loaded inside liposomes estimating their entrapment efficiency, loading efficiency, and in vivo plasma kinetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.